EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 234 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR The Caregiver Curve March 15, 2021 COVID-19 Vaccines May Be Less Effective in Some People with Cancer May 26, 2021 Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... April 22, 2021 Load more HOT NEWS FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer ¿Puede una biopsia hacer que mi cáncer se disemine? New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... What to Know About Treatment Options Before and After Surgery for...
